Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 28809610

Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m(2)) and the Currently Approved Dose (25 mg/m(2)) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2017 Oct 1
First author
Eisenberger M

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2017 Oct 1;35(28):3175-3177. doi: 10.1200/JCO.2017.74.7931.
    note
    Source null
    related pmid
    28809609
    relationship
    Comment in
  2. citation
    J Clin Oncol. 2018 Mar 10;36(8):826-827. doi: 10.1200/JCO.2017.76.3748.
    note
    Source null
    related pmid
    29373098
    relationship
    Comment in
  3. citation
    J Clin Oncol. 2018 Mar 10;36(8):825-826. doi: 10.1200/JCO.2017.75.9829.
    note
    Source null
    related pmid
    29373099
    relationship
    Comment in

Authors and identifiers

  1. name
    Eisenberger M
    type
    Author
  2. name
    Hardy-Bessard AC
    type
    Author
  3. name
    Kim CS
    type
    Author
  4. name
    Géczi L
    type
    Author
  5. name
    Ford D
    type
    Author
  6. name
    Mourey L
    type
    Author
  7. name
    Carles J
    type
    Author
  8. name
    Parente P
    type
    Author
  9. name
    Font A
    type
    Author
  10. name
    Kacso G
    type
    Author
  11. name
    Chadjaa M
    type
    Author
  12. name
    Zhang W
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Eisenberger M
    type
    Author
  2. name
    Hardy-Bessard AC
    type
    Author
  3. name
    Kim CS
    type
    Author
  4. name
    Géczi L
    type
    Author
  5. name
    Ford D
    type
    Author
  6. name
    Mourey L
    type
    Author
  7. name
    Carles J
    type
    Author
  8. name
    Parente P
    type
    Author
  9. name
    Font A
    type
    Author
  10. name
    Kacso G
    type
    Author
  11. name
    Chadjaa M
    type
    Author
  12. name
    Zhang W
    type
    Author
bibliography ids
  1. nci-bib-5171bd383dffaecb74484560
book metadata
content sha256
d42ebe39531c8b6bfdcb86f648b9eb93a5c94e080f1b8f7d9a6616b92cd6be13
document type
citation
dois
  1. 10.1200/JCO.2016.72.1076
electronic publication date
display
2017 Aug 15
precision
day
year
2017
evidence scope
bibliographic_metadata_only
id
pubmed:28809610
immutable id
pubmed:28809610@d42ebe39531c8b6bfdcb86f648b9eb93a5c94e080f1b8f7d9a6616b92cd6be13
journal
abbreviation
J Clin Oncol
issn electronic
1527-7755
issn print
0732-183X
issue
28
name
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
nlm unique id
8309333
pages
3198-3206
volume
35
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2017 Oct 1;35(28):3175-3177. doi: 10.1200/JCO.2017.74.7931.
    note
    Source null
    related pmid
    28809609
    relationship
    Comment in
  2. citation
    J Clin Oncol. 2018 Mar 10;36(8):826-827. doi: 10.1200/JCO.2017.76.3748.
    note
    Source null
    related pmid
    29373098
    relationship
    Comment in
  3. citation
    J Clin Oncol. 2018 Mar 10;36(8):825-826. doi: 10.1200/JCO.2017.75.9829.
    note
    Source null
    related pmid
    29373099
    relationship
    Comment in
outcomes validated
false
pmid
28809610
provenance
batch id
fb25b16edcb1373b70c1
provider
NCBI PubMed ESummary
record sha256
8800de95e27914a83e298f1ba0e03df29e888047bfebc82b9015e4d7e9448cfa
response sha256
182c99bf1974b58308315b66aa28d31c61e8fc31cf3de4cadb0340a4f6734c52
retrieved at
2026-09-09T23:47:28.490065+00:00
publication date
display
2017 Oct 1
precision
day
year
2017
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/28809610/
title
Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m(2)) and the Currently Approved Dose (25 mg/m(2)) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.

Preserved source evidence · Not medical advice